Glaxo Sues To Protect Zofran Patent

Law360, New York (September 30, 2005, 12:00 AM EDT) -- GlaxoSmithKline will go back to court to defend one of the patents for its anti-nausea drug Zofran, the challenge coming this time from generic drug maker Eon Laboratories.

On August 9, Glaxo received notice that Eon, which recently merged with Sandoz Laboratories, had filed an Abbreviated New Drug Application seeking permission to produce a generic version of the drug.

In the complaint, Glaxo contends that Eon’s ANDA violates a patent it holds for “process and composition using ondansetron,” the active ingredient in Zofran. Glaxo was awarded...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.